Strong underlying demand for cancer treatment driving radiotherapy
Increasing global cancer burden through growing incidence and prevalence as people live longer and cancer survival rates are rising globally.
![](/images/39c0952f-edae-4502-8196-5c966a62b9c1/ta-l/placeholder.png)
Avarage life expectancy continues to increase.
Millions
Growing cancer incidence and prevalence.
Millions
Higher survival rates imply cancer as a chronic condition
Technological innovations improve radiotherapy (RT) treatment and more cancer types become relevant for radiotherapy.
Unity, our MR-Linac (MRL), that combines a linear accelerator (linac) with magnetic resonance imaging (MRI) is changing the RT market.
Clinical need for MRL
MRL treatment would be bene-ficial to 25-30% of all RT patients
MRL is expanding the role of RT for indications like:
- Liver cancer
- Stomach cancer
- Cervix/Uterus cancer
- Pancreas cancer
- Head & neck cancer
- Oligo metastatic disease
- Oesophagus cancer
- Lung cancer
Large structural differences in the availability of cancer care around the globe.
RT market still largely underpenetrated in many geographies.
![](/images/5195c735-54c1-4224-9dd3-d91d5ccac116/ta-l/worldmap.jpg)
Expected number of new cancer cases 2025 (million new cases)
Expected yearly growth in cancer cases 2020-25
Number of RT units per capita 2021 (million population)
Increasing healthcare spending putting cost pressure on clinics, thus focusing on value-based healthcare to the benefit of cost-efficient treatments like RT.
Radiotherapy most cost efficient form of cancer treatment